Warning letter
BioLife Plasma Services, L.P.: warning letter of Mar 3, 2003
FDA warning letter UCM147342 · Kansas City District Office
Key facts
| Reference number | UCM147342 |
|---|---|
| Company | BioLife Plasma Services, L.P. |
| Subject | CGMP Regulations for Blood & Blood Components/CGMP for Finished Pharmaceuticals |
| Issue date | Mar 3, 2003 |
| Posted date | Mar 3, 2003 |
| Issuing office | Kansas City District Office |
| Product type | Biologics |
| CFR sections cited | 211.100, 606.20(b), 606.171(c) |
| Country | 3 |
| Inspection city | Saint Joseph |
| Inspection ZIP | 64506-3662 |
| Inspection start date | Jan 13, 2003 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: